ESMO 2018

Viewing 1-20 of 96 articles

ESMO 2018: Preliminary results from TRITON2: A Phase II Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Repair Gene Alterations

2018 ESMO Immuno-Oncology Award Goes to Cornelis Melief

ESMO 2018: The Best of Munich 2018 Congress Genitourinary Tumors, Prostate

ESMO 2018: Can Biology Help Guide Treatment Decisions in Renal Cancer?

ESMO 2018: The Best of Munich 2018 Congress - Genitourinary Tumors, Non-Prostate

ESMO 2018: Challenging Established Frontline Therapies in Renal Cancer

ESMO 2018: WHO-ESMO Workforce Survey: How Can your Country Assure Enough Oncologists for the Future?

ESMO 2018: Where Does the World Stand on Global Cancer Control?

ESMO 2018: Invited Discussant - Genomics of Prostate Cancer for Precision Medicine Based on DNA Repair Defects

ESMO 2018: Invited Discussant - Detection of Circulating Tumor DNA in mHSPC and LATITUDE Study

ESMO 2018: Invited Discussant - mCRPC with High Tumor Mutational Burden and a Phase I Dose-Escalation Study of 177Lu-PSMA-617 for mCRPC

ESMO 2018: How Many Patients Can One Oncologist Care For?

ESMO 2018: Improving Treatment Outcome by Manipulating the Immune System

ESMO 2018: Randomized Trial of ADT + Enzalutamide Versus ADT + Bicalutamide in Metastatic Hormone Sensitive Prostate Cancer

ESMO 2018: Cabazitaxel Treatment in mCRPC Clinical Trials Compared to Usual Care In CAPRI: An Observational Study In The Netherlands

ESMO 2018: Improving Outcome by Optimizing Combination and Sequencing of Treatments

ESMO 2018: Improving Treatment Outcome by Dissecting Heterogeneity

ESMO 2018: Results of PROSPER by Age and Region - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide in Men with nmCRPC

ESMO 2018: PRINCIPAL Study - Real-World Effectiveness of Pazopanib in Patients with Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

ESMO 2018: Safety and Tolerability of Atezolizumab plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma: IMmotion 150 and IMmotion 151

1
2
3
4
5